Abstract
Nine novel mono-oxime reactivators bearing xylene linker were synthesized in an effort to improve previously prepared xylene bisoximes and monocarbamoyl-monooximes. The novel compounds were tested in vitro on the model of tabun-, paraoxon-, methylparaoxon- and DFP-inhibited human erythrocyte AChE. Their reactivation ability was compared to pralidoxime, asoxime, obidoxime and two previously prepared xylene linked bisoximes (K107, K108). All compounds showed minimal reactivation of tabun-inhibited AChE at selected concentration scale. This finding was explained by molecular modelling study. Bisoximes obidoxime and K108 resulted as the best reactivators for paraoxon-, methylparaoxon- and DFP-inhibited AChE. The loss of nonoxime moiety lead to the loss of reactivation ability within the novel compounds. Though the novel reactivators did not exceed previously known compounds, they confirmed former SAR findings for xylene-linked AChE reactivators.
Keywords: Acetylcholinesterase, tabun, DFP, pesticide, reactivator, oxime, xylene linker.
Medicinal Chemistry
Title:Monooxime Bispyridinium Reactivators Bearing Xylene Linker Synthesis and In Vitro Evaluation on Model of Organophosphate-Inhibited Acetylcholinesterase
Volume: 12 Issue: 4
Author(s): Kamil Musilek, Jan Hambalek, Ondrej Holas, Vlastimil Dohnal and Kamil Kuca
Affiliation:
Keywords: Acetylcholinesterase, tabun, DFP, pesticide, reactivator, oxime, xylene linker.
Abstract: Nine novel mono-oxime reactivators bearing xylene linker were synthesized in an effort to improve previously prepared xylene bisoximes and monocarbamoyl-monooximes. The novel compounds were tested in vitro on the model of tabun-, paraoxon-, methylparaoxon- and DFP-inhibited human erythrocyte AChE. Their reactivation ability was compared to pralidoxime, asoxime, obidoxime and two previously prepared xylene linked bisoximes (K107, K108). All compounds showed minimal reactivation of tabun-inhibited AChE at selected concentration scale. This finding was explained by molecular modelling study. Bisoximes obidoxime and K108 resulted as the best reactivators for paraoxon-, methylparaoxon- and DFP-inhibited AChE. The loss of nonoxime moiety lead to the loss of reactivation ability within the novel compounds. Though the novel reactivators did not exceed previously known compounds, they confirmed former SAR findings for xylene-linked AChE reactivators.
Export Options
About this article
Cite this article as:
Musilek Kamil, Hambalek Jan, Holas Ondrej, Dohnal Vlastimil and Kuca Kamil, Monooxime Bispyridinium Reactivators Bearing Xylene Linker Synthesis and In Vitro Evaluation on Model of Organophosphate-Inhibited Acetylcholinesterase, Medicinal Chemistry 2016; 12 (4) . https://dx.doi.org/10.2174/1573406411666151002125640
DOI https://dx.doi.org/10.2174/1573406411666151002125640 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Radioligands for the PET Imaging of Metabotropic Glutamate Receptor Subtype 5 (mGluR5)
Current Topics in Medicinal Chemistry Pharmacologic Treatments in “Prodromal Psychosis:” Making Clinical Decisions in the Absence of a Consensus
Adolescent Psychiatry Neuroprotection by vitamin C against ethanol -induced neuroinflammation associated neurodegeneration in developing rat brain
CNS & Neurological Disorders - Drug Targets Pregabalin Dependence: A Case Report
Current Drug Safety New Ways of Thinking and New Treatment Approaches
Adolescent Psychiatry The Anandamide Degradation System as Potential Target for the Treatment of Central Nervous System Related Disorders
Current Medicinal Chemistry - Central Nervous System Agents Induced Stem Cells as a Novel Multiple Sclerosis Therapy
Current Stem Cell Research & Therapy RETRACTED: Human Suicide, Modern Diagnosis Assistance and Magic Bullet Discovery
Central Nervous System Agents in Medicinal Chemistry Gender Disparity in Pediatric Diseases
Current Molecular Medicine Origin and Expansion of Trinucleotide Repeats and Neurological Disorders
Current Genomics The Glutamatergic Aspects of Schizophrenia Molecular Pathophysiology: Role of the Postsynaptic Density, and Implications for Treatment
Current Neuropharmacology Immuno-Modulatory Properties of a Quinolin-2-(1H)-on-3-Carboxamide Derivative: Relevance in Multiple Sclerosis
Recent Patents on CNS Drug Discovery (Discontinued) miRNAs Highlights in Stem and Cancer Cells
Mini-Reviews in Medicinal Chemistry Dichotomous Life of DNA Binding High Mobility Group Box1 Protein in Human Health and Disease
Current Protein & Peptide Science MicroRNA Expression Levels in Patients with Hashimoto Thyroiditis: A Single Centre Study
Endocrine, Metabolic & Immune Disorders - Drug Targets ERRATUM
Current Neurovascular Research Oxidative Stress and Mitochondrial Dysfunction in Sepsis: A Potential Therapy with Mitochondria-Targeted Antioxidants
Infectious Disorders - Drug Targets Editorial
Central Nervous System Agents in Medicinal Chemistry Tumor Necrosis Factor-α, a Regulator and Therapeutic Agent on Breast Cancer
Current Pharmaceutical Biotechnology Blood Coagulation as an Intrinsic Pathway for Proinflammation: A Mini Review
Inflammation & Allergy - Drug Targets (Discontinued)